Shortly after Gilead Sciences Inc. (NASDAQ: GILD) announced its $11 billion acquisition of Pharmasett, the company also reported some very promising results on a hepatitis C drug that came in the acquisition. Today, those results were trimmed back and Gilead’s shares are taking a beating in the pre-market.
In the earlier report, the drug, called GS-7977, when used in combination with ribavirin eliminated all symptoms of a certain type of hepatitis C in just four weeks. Today’s report indicates that in a certain type of the disease, test results showed that six of eight patients “experienced viral relapse.”
Gilead shares are down nearly -19% at $44.50 in the pre-market.
Gilead’s announcement is available here.
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
